Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Hair loss while taking Mounjaro is typically caused by several interconnected factors: rapid weight loss, nutritional deficiencies (especially protein, iron, zinc, and biotin), hormonal shifts, and physiological stress triggered by the medication's metabolic effects. This condition, often called telogen effluvium, usually appears 2–4 months after starting treatment.
Because hair loss can also signal underlying issues unrelated to Mounjaro—such as thyroid dysfunction, anemia, or autoimmune conditions—it's important to identify the true cause before assuming it's medication-related. Taking a free, instant, online symptom check can help you evaluate your specific symptoms, uncover possible causes, and guide your next steps—whether that's adjusting your nutrition, speaking with your prescriber, or ruling out other health concerns.
Reviewed for medical accuracy: 07/10/2026
Mounjaro (tirzepatide) is a newer medication approved for type 2 diabetes and, more recently, for weight management. As its use grows, some people report thinning hair or increased shedding. Understanding why does Mounjaro cause hair loss, what to watch for, and when to consider a different treatment can help you make informed choices without undue worry.
Most people experience improved glucose control, often accompanied by significant weight reduction. While these effects are generally positive, sudden changes in body weight and metabolism can impact hair growth cycles.
There isn't a single, proven mechanism linking tirzepatide directly to hair loss. Instead, several factors related to the drug and its effects may play a role:
Rapid Weight Loss & Telogen Effluvium
Nutritional Changes
Hormonal Fluctuations
Stress on the Body
Direct Drug Effects (Theoretical)
Hair loss on Mounjaro often presents as:
If you're experiencing these symptoms and want to better understand what might be causing them, take Ubie's free AI symptom checker to get personalized insights and find out whether you should consult a healthcare provider.
Review Your Diet & Supplements
Manage Stress & Sleep
Use Gentle Hair Care
Monitor Your Weight-Loss Rate
Track Your Medications & Health Changes
Do a Symptom Check
Deciding whether to continue Mounjaro or switch to another treatment depends on multiple factors:
Each option has its own profile for blood sugar control, weight impact, and side effects. Always discuss these in detail with your healthcare provider.
When you visit your doctor or endocrinologist, bring:
Questions to ask:
While most Mounjaro-related hair loss is non-life-threatening, contact your doctor if you experience:
Hair loss linked to Mounjaro often stems from rapid weight loss, nutritional shifts, and temporary stress on the body. In many cases, shedding improves with diet adjustments, stress management, and time. If hair loss persists or worsens, consult your doctor to explore lab tests, supplements, dose adjustments, or alternative diabetes medications.
Always speak to a healthcare professional before making any changes that could affect your overall health or diabetes control.
(References)
* Ali A, Aljaber A, Almutawa M, Alshubaili K. Alopecia as a Side Effect of Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis. Cureus. 2024 Jan 15;16(1):e52358. doi: 10.7759/cureus.52358. PMID: 38356973; PMCID: PMC10866037.
* Kim S, Lee Y, Jeon M, Jin SM, Hong JJ, Kim H. Hair loss during tirzepatide treatment for type 2 diabetes and obesity: a systematic review. Diabetes Metab Syndr Obes. 2024 Jan 22;17:395-403. doi: 10.2147/DMSO.S447155. PMID: 38283404; PMCID: PMC10821865.
* Hepprich M, Schneiter S, Schultes B. Tirzepatide for the Treatment of Type 2 Diabetes and Obesity: An Overview of the SURPASS and SURMOUNT Clinical Trial Programs. Diabetes Metab Syndr Obes. 2023 Feb 1;16:323-344. doi: 10.2147/DMSO.S397072. PMID: 36761184; PMCID: PMC9903912.
* Wu D, Wen X, Zhou Y, Han P, Yang Y, Zhang Y, Gao Y, Cui S, Liu X. Safety and efficacy of tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023 Mar 1;14:1120019. doi: 10.3389/fendo.2023.1120019. PMID: 36923832; PMCID: PMC10013233.
* Parfitt JR, Basra R, Farooqi A, Gopinath P. Telogen Effluvium after Bariatric Surgery: Is It Preventable? Obes Surg. 2020 Jan;30(1):319-322. doi: 10.1007/s11695-019-04140-5. PMID: 31485926.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.